BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 2016;30:1607-15. [PMID: 27243774 DOI: 10.1097/QAD.0000000000001098] [Cited by in Crossref: 80] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
3 Foreman TW, Bucşan AN, Mehra S, Peloquin C, Doyle LA, Russell-Lodrigue K, Gandhi NR, Altman J, Day CL, Ernst JD, Blumberg HM, Rengarajan J, Kaushal D. Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques. Am J Respir Crit Care Med 2020;201:469-77. [PMID: 31647877 DOI: 10.1164/rccm.201903-0646OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
4 Hatherill M, White RG, Hawn TR. Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Front Microbiol 2019;10:3154. [PMID: 32082273 DOI: 10.3389/fmicb.2019.03154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
5 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69:1-11. [PMID: 32053584 DOI: 10.15585/mmwr.rr6901a1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 54.0] [Reference Citation Analysis]
6 Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep 2018;67:723-6. [PMID: 29953429 DOI: 10.15585/mmwr.mm6725a5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 17.0] [Reference Citation Analysis]
7 Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, Dobos KM, Kellogg A, McLaughlin M, McManus M, Alfaro RM, Hadigan C, Kovacs JA, Kumar P. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis 2018;67:193-201. [PMID: 29415190 DOI: 10.1093/cid/ciy082] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
8 Shin H, Jo Y, Chaisson RE, Turner K, Churchyard G, Dowdy DW. Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV. J Int AIDS Soc 2020;23:e25629. [PMID: 33107219 DOI: 10.1002/jia2.25629] [Reference Citation Analysis]
9 Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A;  IMPAACT P1078 TB APPRISE Study Team. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019;381:1333-1346. [PMID: 31577875 DOI: 10.1056/nejmoa1813060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
10 Yang HJ, Wang D, Wen X, Weiner DM, Via LE. One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics. Front Cell Infect Microbiol 2021;11:613149. [PMID: 33796474 DOI: 10.3389/fcimb.2021.613149] [Reference Citation Analysis]
11 Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019;380:1001-11. [PMID: 30865794 DOI: 10.1056/NEJMoa1806808] [Cited by in Crossref: 110] [Cited by in F6Publishing: 49] [Article Influence: 55.0] [Reference Citation Analysis]
12 Jeon D. Latent tuberculosis infection: recent progress and challenges in South Korea. Korean J Intern Med 2020;35:269-75. [PMID: 32131570 DOI: 10.3904/kjim.2020.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
13 Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, Nuermberger E, Kim P, Barry CE, Owen A, Hazuda D, Flexner C. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis 2018;22:125-32. [PMID: 29506608 DOI: 10.5588/ijtld.17.0486] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
14 Boyd AT, Lodiongo DK, Benson JM, Aragaw S, Pasquale MS, Ayalneh H, Olemukan R, Avaku I, Baabe N, Achut V, Chun H, Bunga S. Implementation of tuberculosis preventive treatment among people living with HIV, South Sudan. Bull World Health Organ 2021;99:34-40. [PMID: 33716332 DOI: 10.2471/BLT.20.254789] [Reference Citation Analysis]
15 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
16 Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M. Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab319. [PMID: 34395707 DOI: 10.1093/ofid/ofab319] [Reference Citation Analysis]
17 Marais BJ. Newer Drugs for Tuberculosis Prevention and Treatment in Children. Indian J Pediatr 2019;86:725-31. [PMID: 30707347 DOI: 10.1007/s12098-018-02854-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Scolarici M, Dekitani K, Chen L, Sokol-Anderson M, Hoft DF, Chatterjee S. A scoring strategy for progression risk and rates of treatment completion in subjects with latent tuberculosis. PLoS One 2018;13:e0207582. [PMID: 30440033 DOI: 10.1371/journal.pone.0207582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Kidwai S, Park CY, Mawatwal S, Tiwari P, Jung MG, Gosain TP, Kumar P, Alland D, Kumar S, Bajaj A, Hwang YK, Song CS, Dhiman R, Lee IY, Singh R. Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2017;61:e00969-17. [PMID: 28893784 DOI: 10.1128/AAC.00969-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
20 Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. J Clin Microbiol 2020;58:e00393-20. [PMID: 32245831 DOI: 10.1128/JCM.00393-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
21 Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence. J Int AIDS Soc 2020;23:e25481. [PMID: 32202066 DOI: 10.1002/jia2.25481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
23 Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, Sean Cavanaugh J. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther 2020;17:40. [PMID: 32650797 DOI: 10.1186/s12981-020-00296-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Am J Prev Med 2018;55:244-52. [PMID: 29910114 DOI: 10.1016/j.amepre.2018.04.030] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
25 Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016;316:191-210. [PMID: 27404187 DOI: 10.1001/jama.2016.8900] [Cited by in Crossref: 400] [Cited by in F6Publishing: 364] [Article Influence: 80.0] [Reference Citation Analysis]
26 Lam E, Schaefer J, Zheng R, Zhan T, Kraft WK. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. Clin Transl Sci 2020;13:1244-50. [PMID: 32407548 DOI: 10.1111/cts.12810] [Reference Citation Analysis]
27 Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS 2019;33:525-36. [PMID: 30325773 DOI: 10.1097/QAD.0000000000002053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Marks SM, Dowdy DW, Menzies NA, Shete PB, Salomon JA, Parriott A, Shrestha S, Flood J, Hill AN. Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination. Public Health Rep 2020;135:38S-43S. [PMID: 32735183 DOI: 10.1177/0033354920912710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR Jr, Marks SM, Linas BP. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. JAMA Intern Med 2017;177:1755-64. [PMID: 29049814 DOI: 10.1001/jamainternmed.2017.3941] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
30 Sanju Sv C, Srinivasapura Venkateshmurthy N, Nair D, Hari Ankolekar V, Mv Kumar A. What Proportion of New Tuberculosis Patients Has a History of Household Tuberculosis Exposure? A Cross-Sectional Study from Udupi District, South India. Trop Med Infect Dis 2019;4:E133. [PMID: 31683771 DOI: 10.3390/tropicalmed4040133] [Reference Citation Analysis]
31 Gersh JK, Barnabas RV, Matemo D, Kinuthia J, Feldman Z, Lacourse SM, Mecha J, Warr AJ, Kamene M, Horne DJ. Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya. BMC Infect Dis 2021;21:218. [PMID: 33632173 DOI: 10.1186/s12879-021-05916-z] [Reference Citation Analysis]
32 Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, Menzies D. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Med 2021;18:e1003738. [PMID: 34520459 DOI: 10.1371/journal.pmed.1003738] [Reference Citation Analysis]
33 Fry SH, Barnabas SL, Cotton MF. Tuberculosis and HIV-An Update on the "Cursed Duet" in Children. Front Pediatr 2019;7:159. [PMID: 32211351 DOI: 10.3389/fped.2019.00159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Glob Public Health 2021;:1-14. [PMID: 33650939 DOI: 10.1080/17441692.2021.1892793] [Reference Citation Analysis]